Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1998 1
2003 2
2004 1
2005 1
2008 1
2013 1
2017 1
2018 1
2020 6
2021 6
2022 3
2023 3
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M; ExteNET Study Group. Chan A, et al. Among authors: alonso mg. Clin Breast Cancer. 2021 Feb;21(1):80-91.e7. doi: 10.1016/j.clbc.2020.09.014. Epub 2020 Oct 6. Clin Breast Cancer. 2021. PMID: 33183970 Free article. Clinical Trial.
Training and pandemic.
Alonso MG. Alonso MG. Rev Esp Cir Ortop Traumatol (Engl Ed). 2021 May-Jun;65(3):165-166. doi: 10.1016/j.recote.2021.04.001. Epub 2021 Apr 14. Rev Esp Cir Ortop Traumatol (Engl Ed). 2021. PMID: 34040679 Free PMC article. No abstract available.
TRAINING AND PANDEMIC.
Alonso MG. Alonso MG. Rev Esp Cir Ortop Traumatol (Engl Ed). 2021 May-Jun;65(3):165-166. doi: 10.1016/j.recot.2021.03.001. Rev Esp Cir Ortop Traumatol (Engl Ed). 2021. PMID: 33865552 Free PMC article. English, Spanish. No abstract available.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer.
Fernandez LM, São Julião GP, Santacruz CC, Renehan AG, Cano-Valderrama O, Beets GL, Azevedo J, Lorente BF, Rancaño RS, Biondo S, Espin-Basany E, Vailati BB, Nilsson PJ, Martling A, Van De Velde CJH, Parvaiz A, Habr-Gama A, Perez RO; International Watch & Wait Database Consortium (IWWD) and the Spanish Rectal Cancer Viking Consortium (VIKINGO); International Watch & Wait Database Consortium (IWWD) & Spanish Rectal Cancer Viking Consortium. Fernandez LM, et al. J Clin Oncol. 2025 May 10;43(14):1663-1672. doi: 10.1200/JCO.24.00405. Epub 2024 Oct 28. J Clin Oncol. 2025. PMID: 39467217 Free PMC article.
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Mc Laughlin AM, et al. Clin Pharmacol Ther. 2024 Sep;116(3):690-702. doi: 10.1002/cpt.3238. Epub 2024 Mar 18. Clin Pharmacol Ther. 2024. PMID: 38494911
"Long-term oncologic outcomes and risk factors for distant recurrence after pathologic complete response following neoadjuvant treatment for locally advanced rectal cancer. A nationwide, multicentre study".
Cerdán-Santacruz C, Cano-Valderrama Ó, Santos Rancaño R, Terés LB, Vigorita V, Pérez TP, Rosciano Paganelli JG, Paredes Cotoré JP, Carre MK, Flor-Lorente B; Collaborating group for the study of long-term oncologic results of pathologic complete response in locally advanced rectal cancer patients; Spanish Rectal Cancer Project (Vikingo); Antona FB, Martín EY, Tebar JC, Cao IA, Coltell ZB, Alonso MG, Paredes Cotoré JP, Prada López BL, Riesco AB, Cánovas NI, Sánchez CM, Serrat DR, Conde GA, Toscano MJ, Aira AC, Pérez MR, Petit NM, Espín Basany E, Carré MK, Pellino G, Retuerta JM, Saldaña AG, Laso CÁ, Allende IA, Álvarez DH, Cazador AC, Sánchez Bautista WM, Torres Sánchez MT, Bonito AC, Velázquez MC, Díaz OM, Fuentes NS, Olías MDCV, Pérez TP, Rosciano Paganelli JG, Lorente BF, Valderrama ÓC, Santos Rancaño R, Terés LB, Santacruz CC. Cerdán-Santacruz C, et al. Among authors: alonso mg. Eur J Surg Oncol. 2023 Oct;49(10):106962. doi: 10.1016/j.ejso.2023.06.014. Epub 2023 Jun 29. Eur J Surg Oncol. 2023. PMID: 37414628
29 results